TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8957583
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg once daily
Study: 8452167
Drug: Ceftazidime 0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 0.5-2 g three times a day or 1-2 g twice a day
Study: 3085738
Drug: Sodium Valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Valproate (SV) 800 mg
Study: 27508937
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT) in addition to care as usual (CAU), n = 65
Study: 22632734
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D(3) supplementation 1600 IU (40 μg) per day
Study: 20420759
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (HFM) (50 g fat)
Study: 20420759
Drug: Low-fat, high-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat, high-carbohydrate meal (HCM) (5 g fat)
Study: 11115412
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg daily for 4 weeks)
Study: 9117878
Drug: RV16 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV16 treatment (0.5-2.9 x 10(4) TCID50)
Study: 9117878
Drug: RV16 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV16 treatment
Study: 30376095
Drug: 1 IPV
Normalized name: IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 IPV at 8 weeks followed by 2 doses of bOPV
Study: 30376095
Drug: Second IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second IPV dose at 16 weeks
Study: 30376095
Drug: Sequential IPV-bOPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IPV-bOPV
Study: 24711637
Drug: Biocompatible PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible PD solution
Study: 21262565
Drug: Aripiprazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (up to 15 mg/day)
Study: 15781762
Drug: Desloratadine, 5
Normalized name: Desloratadine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine, 5 mg/d
Study: 17165277
Drug: Levocetirizine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine, 5 mg/d
Study: 17165277
Drug: Montelukast, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 5 mg/d
Study: 17165277
Drug: Montelukast +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast + Antihistamine (Desloratadine or Levocetirizine)
Study: 17165277
Drug: Montelukast +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast + Antihistamine
Study: 10892625
Drug: Functional electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional electrical stimulation (FES) therapy, 6 hours/day for 6 weeks, targeting supraspinatus and posterior deltoid muscles.
Study: 1356519
Drug: Ebrotidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine (800 mg)
Study: 30945430
Drug: Moisturizer containing
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese (experimental cream)
Study: 30945430
Drug: 0.02% Triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% Triamcinolone acetonide cream (TA cream)
Study: 26859481
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - no supplement
Study: 24863949
Drug: Vildagliptin-metformin combination
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin-metformin combination regimen
Study: 24863949
Drug: Standard-of-care metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care metformin monotherapy
Study: 22175269
Drug: Prescription review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription review sent to physician
Study: 22175269
Drug: Prescription review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription review sent to physician and current comprehensive medication record sent to the patient
Study: 18418965
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) group treated with aspirin, Clopidogrel, statins
Study: 18418965
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) group treated with Dahuang Zhechong Pill, Tianma Duzhong Capsule, and self‐formulated decoctions
Study: 18418965
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (IM) group treated with both TCM and WM
Study: 14606705
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg Talpha1 (low dose group; n = 8)
Study: 14606705
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg Talpha1 (high dose group; n = 8)
Study: 8894384
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support system for oral hypoglycaemic therapy
Study: 30021449
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (IG)
Study: 30021449
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (DG)
Study: 30021449
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of early treatment
Study: 27287084
Drug: LNG/EE extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE extended regimen (84 days of LNG 150 μg/EE 30 μg with 7 days of EE 10 μg)
Study: 27287084
Drug: LNG/EE 21/7
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE 21/7 (21 days of LNG 100 μg/EE 20 μg with 7 days of placebo)
Study: 17262225
Drug: Categories of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Categories of assessment for esthetic evaluation, functional assessment, biological responses to restorative materials
Study: 14973528
Drug: Colchicine 0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5-2.5 mg daily for 4 months
Study: 11245843
Drug: Target merging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target merging (merging pairs of items, e.g., connecting item locations with a line segment or drawing the convex hull)
Study: 9840855
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) guidance with 20 mL 0.5% bupivacaine
Study: 9840855
Drug: Nerve stimulator
Normalized name: nerve stimulator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator (NS) guidance with 20 mL 0.5% bupivacaine
Study: 9840855
Drug: Nerve stimulator
Normalized name: nerve stimulator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator (NS) guidance with 30 mL 0.5% bupivacaine
Study: 2510959
Drug: Urokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase therapy (two weeks administration)
Study: 2510959
Drug: Urokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase therapy (consecutive administration)
Study: 2510959
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs (control)
Study: 26353947
Drug: Non-metformin antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-metformin antidiabetic medications
Study: 26353947
Drug: No antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antidiabetic medication
Study: 2254723
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment (ICT, n = 44)
Study: 2254723
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (RT, n = 53)
Study: 6402199
Drug: Dihydrocodeine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 15 mg
Study: 29325486
Drug: Intensive client-centred
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive client-centred occupational therapy (ICC-OT) - maximum 22 sessions
Study: 29325486
Drug: Usual practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual practice - maximum 3 sessions of occupational therapy
Study: 31159805
Drug: Structured information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured information delivery, personalised written physical activity prescription (number of steps per day), pedometer, and pedometer logbook.
Study: 31159805
Drug: Structured information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured information delivery, personalised written physical activity prescription, pedometer, and pedometer logbook.
Study: 18278978
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 150 mg/day
Study: 17099376
Drug: Intravenous cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefuroxime 750 mg just before the procedure followed by two further doses every 8 h (Group A)
Study: 17099376
Drug: Single application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single application of povidone-iodine (Betadine) antiseptic spray (Group B)
Study: 17099376
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cefuroxime and Betadine spray (Group C)
Study: 12958051
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus O2
Study: 9308557
Drug: Prilocaine-lidocaine patch
Normalized name: lidocaine / prilocaine Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine-lidocaine patch (anesthetic patch)
Study: 8346498
Drug: Nicotine (0.08‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.08‐2.0 mg)
Study: 8346498
Drug: Nicotine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2.0 mg given eight times daily for nine days)
Study: 8346498
Drug: Histamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine challenge after acute doses of nicotine
Study: 8346498
Drug: Histamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine challenge during prolonged treatment with nicotine
Study: 2940370
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment methods (B regimen)
Study: 23913968
Drug: Basiliximab/low-dose rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab/low-dose rabbit anti-thymocyte globulin (Bas/rATG)
Study: 21429514
Drug: Protein-enriched diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched diet (1.1 g protein/100 mL of feeding formula)
Study: 17006921
Drug: Clonidine (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.075 mg) twice daily for 3 months
Study: 1545089
Drug: Inhaled gallopamil
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled gallopamil (20 mg)
Study: 21521379
Drug: Topical triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triiodothyronine ointment applied twice daily for 12 weeks
Study: 21521379
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 12 weeks
Study: 15965585
Drug: Control conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control conditions (non‐intensified vs. intensified therapy, Bobath approach)
Study: 9673554
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 25 to 30 ml/kg body weight at 37 degrees C infused under the right hemidiaphragm (Group C)
Study: 9673554
Drug: No peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peritoneal infusion, no subhepatic drain (Group A)
Study: 9673554
Drug: No peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peritoneal infusion but a subhepatic closed drain left for 24 hours (Group B)
Study: 8079849
Drug: 125 ml
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 ml of iohexol 350
Study: 8079849
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of iohexol 300
Study: 8079849
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of diatrizoate meglumine 60%
Study: 1017281
Drug: New tar
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tar gel
Study: 25724655
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg or 25 mg
Study: 22327131
Drug: Palifermin 60
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palifermin 60 μg/kg daily for three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning.
Study: 20337955
Drug: Propofol-ketamine combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-ketamine combination
Study: 23564564
Drug: Peg‐IFN group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFN group (31 patients received Peg‐IFN subcutaneously at a dose of 50 μg per week for 12 months)
Study: 23564564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (62 patients followed only, no adjuvant therapies)
Study: 19393000
Drug: Xolair (anti-IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xolair (anti-IgE treatment) for 16 weeks in patients with high IgE fraction (>3.8%)
Study: 19393000
Drug: Xolair (anti-IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xolair (anti-IgE treatment) for 16 weeks in patients with low IgE fraction (<1%)
Study: 16393304
Drug: L. rhamnosus
Normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3) administered at a dose of 1.2 x 10(10) CFU, twice daily, for 5 days
Study: 16393304
Drug: L. rhamnosus
Normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3) in rotavirus infection
Study: 16393304
Drug: L. rhamnosus
Normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. rhamnosus strains (573L/1; 573L/2; 573L/3)
Study: 11357896
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg IV
Study: 11357896
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg orally
Study: 7949622
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a dose of 0.7 IU/kg/week (group B)
Study: 7949622
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) therapy at a dose of 1.4 IU/kg/week (group C)
Study: 2897559
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g once daily)
Study: 2897559
Drug: Gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin plus cefuroxime (combination therapy)
Study: 23704089
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (L-DNR)
Study: 17940996
Drug: Sensitivity and
Normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g ORAL PASTE [SENSODYNE Sensitivity and Gum Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity and specificity measures in treatment groups
Study: 11929349
Drug: Triflusal (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (600 mg/day)
Study: 10378821
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (300 mg/day)
Study: 6638451
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthetic technique of fentanyl and methohexitone
Study: 30618285
Drug: Theta Burst
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theta Burst Stimulation (TBS) + Physical Therapy (PT)
Study: 30618285
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) + Physical Therapy (PT)
Study: 30005654
Drug: Combined resistance
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined resistance exercise training guided by a physiotherapist twice a week and increased protein intake under the supervision of a dietitian
Study: 19114175
Drug: IMVAMUNE (Modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMVAMUNE (Modified Vaccinia Ankara vaccine) followed by Dryvax
Study: 17686255
Drug: Extended-release metformin
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metformin 1500 mg qd for 12 weeks
Study: 17686255
Drug: Glucophage (metformin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage (metformin, 500 mg, tid) for 12 weeks
Study: 1586711
Drug: High-dose rhIL-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhIL-3
Study: 363047
Drug: Carbenicillin administered
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin administered intravenously
Study: 363047
Drug: Carbenicillin administered
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin administered intramuscularly
Study: 28319997
Drug: Single glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single glucocorticoid intradiscal injection (25 mg prednisolone acetate)
Study: 15067204
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg per os)
Study: 15067204
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) (40 mg per os)
Study: 15067204
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) (40 mg per os) during hyperprolactinemia
Study: 9663811
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor preparations
Study: 7820329
Drug: E3810 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3810 single oral doses (1, 3, 10, 20, 40 and 80 mg) in fasting conditions
Study: 7820329
Drug: E3810 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3810 single oral dose (20 mg) after a meal
Study: 7820329
Drug: E3810 repeated
Normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E3810 repeated oral doses (20 and 40 mg) once daily for 7 days
Study: 26100824
Drug: Varenicline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (2 mg single dose)
Study: 21724872
Drug: Daikenchuto (TJ‐100)
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (TJ‐100) 5-g administration
Study: 21724872
Drug: Daikenchuto (TJ‐100)
Normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daikenchuto (TJ‐100) 2.5 to 10 g/day
Study: 15274666
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg daily and tinidazole 500 mg two tablets daily with lansoprazole 30 mg daily for 6 days (ATL-group)
Study: 10992830
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg)
Study: 11071674
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.14 mg/kg)
Study: 11071674
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous and intrathecal)
Study: 8871173
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg) in supplementary experiments
Study: 1386245
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 8 mg of ondansetron followed by a 24 h infusion of 1 mg h‐1 (group 1)
Study: 1386245
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 32 mg of ondansetron (group II)
Study: 1386245
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 8 mg of ondansetron (group III)
Study: 29314146
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) 400 mg + Daclatasvir (DCV) 60 mg daily + weight-based Ribavirin (RBV) for 12 weeks (or 24 weeks if RBV contraindicated)
Study: 29121974
Drug: Minocycline added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline added to treatment as usual (TAU)
Study: 29121974
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids added to treatment as usual (TAU)
Study: 29121974
Drug: Minocycline and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline and/or omega-3 fatty acids added to treatment as usual (TAU)
Study: 26414968
Drug: Spironolactone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25-50 mg)
Study: 10404850
Drug: Immediate-release ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release ranolazine (various dosing regimens)
Study: 2185298
Drug: Daily paracentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily paracentesis (3‐4 litre) and intravenous albumin infusion
Study: 2185298
Drug: Daily paracentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily paracentesis